Showing results (131-140 of 144) with videos related to

Sort By:
Pageof 15
Inflammatory Bowel Diseases|April 23, 2019
Adalimumab or Infliximab for the Prevention of Early Postoperative Recurrence of Crohn Disease: Results From the ENEIDA RegistryFiorella Cañete, Míriam Mañosa, María José Casanova, et al.
Journal of Crohn'S & Colitis|December 5, 2021
Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA RegistryMargalida Calafat, Míriam Mañosa, Elena Ricart, et al.
Digestive Diseases and Sciences|July 17, 2020
Extraintestinal Manifestations in Patients with Inflammatory Bowel Disease: Study Based on the ENEIDA RegistryAlicia Algaba, Iván Guerra, Elena Ricart, et al.
Journal of Crohn'S & Colitis|October 9, 2025
Comprehensive proteomic profile in newly diagnosed patients with inflammatory bowel disease: identification of potential biomarkersMontse Baldán-Martín, Ibon Iloro, Mikel Azkargorta, et al.
Journal of Crohn'S & Colitis|September 24, 2020
Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA RegistryMaría Chaparro, Ana Garre, Francisco Mesonero, et al.
Frontiers in Cellular and Infection Microbiology|July 16, 2025
Exploration of fecal microbiota in newly diagnosed patients with inflammatory bowel disease using shotgun metagenomicsMacarena Orejudo, Manuel J Gómez, Sabino Riestra, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 14, 2024
Psoriasis induced by antiTNF therapy in inflammatory bowel disease: Therapeutic management and evolution of both diseases in a nationwide cohort studyPatricia Sanz Segura, Fernando Gomollón, Diego Casas, et al.
Postgraduate Medical Journal|June 24, 2024
Influence of familial forms of inflammatory bowel disease on the use of immunosuppressants, biological agents, and surgery in the era of biological therapies. Results from the ENEIDA projectCarlos González-Muñoza, Margalida Calafat, Javier P Gisbert, et al.
Gut|January 11, 2025
Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCUJavier P Gisbert, María G Donday, Sabino Riestra, et al.
Alimentary Pharmacology & Therapeutics|August 8, 2025
Frequency and Effectiveness of Dose Escalation and De-Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW-IBD Study of ENEIDACristina Rubín de Célix, Elena Ricart, M Dolores Martín-Arranz, et al.
Pageof 15